Antiplatelet therapy for prevention of death, myocardial infarction, and stroke
17 results
1 - 17Antiplatelet therapy for prevention of death, myocardial infarction, and stroke
Antithrombotic agents in primary health care
Antiplatelet agents and anticoagulants for hypertension
Cerebral infarction (ischaemic stroke)
Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack Edited (no change to conclusions)
Antiplatelet agents and anticoagulants for hypertension New search for studies and content updated (no change to conclusions)
Low-dose aspirin for primary prevention of vascular events in type 2 diabetes
Oral anticoagulants vs antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or TIA
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment: Cochrane systematic review